• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: FERRING PHARMACEUTICALS INC. EUFLEXXA 10MG/ML 2ML ACID, HYALURONIC, INTRAARTICULAR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

FERRING PHARMACEUTICALS INC. EUFLEXXA 10MG/ML 2ML ACID, HYALURONIC, INTRAARTICULAR Back to Search Results
Device Problem Insufficient Information (3190)
Patient Problem Insufficient Information (4580)
Event Type  Injury  
Event Description
Pt reported that she had back surgery about 4 weeks ago. This will be arxwps first fill for the pt. Md: (b)(6).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand NameEUFLEXXA 10MG/ML 2ML
Type of DeviceACID, HYALURONIC, INTRAARTICULAR
Manufacturer (Section D)
FERRING PHARMACEUTICALS INC.
MDR Report Key12852450
MDR Text Key281165661
Report NumberMW5105498
Device Sequence Number1
Product Code MOZ
Combination Product (y/n)N
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Voluntary
Reporter Occupation Pharmacist
Type of Report Initial
Report Date 11/17/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received11/19/2021
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes

Patient Treatment Data
Date Received: 11/19/2021 Patient Sequence Number: 1
Treatment
ALBUTEROL HFA; ATORVASTATIN ; BUSPIRONE; CEPHALEXIN ; CLOPIDOGREL ; CYCLOBENZAPR ; DICLOFENAC GEL ; DULOXETINE; MIRTAZAPINE; MYRBETRIQ; NORTRIPTYLIN; ORPHENADRINE ER ; TRAZODONE
-
-